Mirum Pharmaceuticals (MIRM) Expected to Announce Quarterly Earnings on Wednesday

Mirum Pharmaceuticals (NASDAQ:MIRM) will likely be posting its quarterly earnings results after the market closes on Wednesday, February 26th. Analysts expect Mirum Pharmaceuticals to post earnings of ($0.27) per share and revenue of $96.64 million for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Mirum Pharmaceuticals Stock Performance

NASDAQ MIRM opened at $50.95 on Tuesday. Mirum Pharmaceuticals has a 52-week low of $23.14 and a 52-week high of $54.23. The stock has a market cap of $2.45 billion, a PE ratio of -25.22 and a beta of 0.96. The firm has a 50-day moving average of $46.38 and a 200-day moving average of $43.20. The company has a debt-to-equity ratio of 1.33, a quick ratio of 3.15 and a current ratio of 3.34.

Insider Activity at Mirum Pharmaceuticals

In related news, insider Joanne Quan sold 6,969 shares of the business’s stock in a transaction on Friday, January 17th. The shares were sold at an average price of $45.86, for a total value of $319,598.34. Following the sale, the insider now owns 5,649 shares of the company’s stock, valued at $259,063.14. The trade was a 55.23 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Christopher Peetz sold 7,489 shares of the firm’s stock in a transaction on Tuesday, January 7th. The stock was sold at an average price of $42.82, for a total value of $320,678.98. Following the transaction, the chief executive officer now directly owns 119,359 shares of the company’s stock, valued at approximately $5,110,952.38. This represents a 5.90 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 40,915 shares of company stock valued at $1,897,920. 22.87% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on MIRM shares. Citigroup lifted their price target on Mirum Pharmaceuticals from $65.00 to $68.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Robert W. Baird boosted their target price on shares of Mirum Pharmaceuticals from $44.00 to $50.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Finally, HC Wainwright reiterated a “buy” rating and issued a $66.00 price objective on shares of Mirum Pharmaceuticals in a research note on Wednesday, November 13th. Ten equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Mirum Pharmaceuticals has an average rating of “Buy” and a consensus price target of $57.10.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.